Business Context and Reporting Period
Company: Agios Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Agios is a commercial-stage biopharmaceutical company focused on rare diseases, primarily hematology. Its lead product, mitapivat, is marketed as PYRUKYND® for pyruvate kinase (PK) deficiency and as AQVESME® for thalassemia. The company recently launched AQVESME® in the U.S. in late January 2026 and is advancing clinical programs for sickle cell disease (SCD), lower-risk myelodysplastic syndromes (LR MDS), phenylketonuria (PKU), and polycythemia vera (PV).
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $20,746 | $8,726 |
| Net Loss | $(99,111) | $(89,289) |
| Net Loss Per Share (Basic & Diluted) | $(1.69) | $(1.55) |
| Operating Expenses | $130,771 | $115,355 |
| Research & Development (R&D) | $81,148 | $72,743 |
| Selling, General & Administrative (SG&A) | $48,304 | $41,527 |
| Cash, Cash Equivalents & Marketable Securities | $1,005,888 | $1,297,225 (Total Assets) |
| Net Cash Used in Operating Activities | $(118,920) | $(111,489) |
Note: Total assets decreased from $1.297 billion (Dec 31, 2025) to $1.185 billion (Mar 31, 2026). Liquidity (cash + marketable securities) stood at approximately $1.0 billion as of March 31, 2026.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $12.0 million (138%) compared to Q1 2025. This was driven by a $10.1 million increase in U.S. revenue (due to the launch of AQVESME® and increased PYRUKYND® volume) and $1.9 million in new "Rest of World" revenue from distribution agreements.
- Expense Increases: Total operating expenses rose by $15.4 million. R&D expenses increased by $8.4 million, primarily due to higher indirect compensation costs and direct process development expenses for PYRUKYND®/AQVESME®. SG&A expenses increased by $6.8 million, driven by commercial launch activities for AQVESME® and higher stock-based compensation.
- Net Loss Expansion: Net loss widened by $9.8 million to $99.1 million, reflecting the increase in operating expenses and a decrease in interest income ($10.8 million vs. $16.1 million in Q1 2025), partially offset by revenue growth.
- Investment Portfolio: Interest income decreased due to a lower average investment balance compared to the prior year.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Regulatory Milestones: The European Commission is reviewing a positive CHMP opinion for PYRUKYND® in thalassemia, with a final decision expected in H1 2026. Agios intends to submit a supplemental New Drug Application (sNDA) for mitapivat in SCD in Q2 2026 following a proposal for a confirmatory clinical trial.
- Commercialization: AQVESME® was commercially launched in the U.S. in late January 2026. The product requires a Risk Evaluation and Mitigation Strategy (REMS) due to potential hepatocellular injury risks.
- Liquidity: Management expects current cash, cash equivalents, and marketable securities ($1.0 billion) to fund operations for at least the next 12 months. No committed external funding sources exist other than potential retain earn-out rights from the sale of the oncology business.
Risks and Contingencies
- REMS Compliance: Failure to comply with the AQVESME® REMS program could result in regulatory action or decreased sales.
- Patent Litigation: An Abbreviated New Drug Application (ANDA) with a Paragraph IV certification for mitapivat was filed on February 17, 2026. Agios intends to file an infringement suit.
- Supply Chain & Geopolitics: Risks include reliance on third-party manufacturers, potential impacts of the BIOSECURE Act on Chinese biotechnology entities, and global trade tariffs.
- Profitability: The company has an accumulated deficit of $660.8 million and expects to continue incurring significant losses until product revenue scales sufficiently.
Investor Verification Checklist
- REMS Implementation: Verify the enrollment rates and operational efficiency of the AQVESME® REMS program, as this is a critical gatekeeper for U.S. sales.
- ANDA Litigation Status: Monitor the progress of the patent infringement lawsuit filed in response to the February 2026 ANDA filing for mitapivat.
- EU Approval Timeline: Confirm the final decision date from the European Commission regarding the thalassemia indication for PYRUKYND®.
- SCD Trial Design: Review the specifics of the confirmatory clinical trial proposal submitted to the FDA for SCD, particularly the primary endpoint changes.
- Cash Burn Rate: Assess the sustainability of the ~$119 million quarterly operating cash burn against the $1.0 billion liquidity position.